Enoxaparin binds to anti-thrombin III leading to inhibition of coagulation factors IIa and Xa. 

It is indicated: 
- for the prophylaxis of venous thromboembolic disorders in post-operative patients.
- for prophylaxis and treatment of venous thromboembolic disease due to acute illness, deep vein thrombosis and pulmonary embolism.
- for the treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin.
- for the treatment of acute ST-segment Elevation Myocardial Infarction including patients to be managed medically or with subsequent Percutaneous Coronary Intervention in conjunction with thrombolytic drugs.
- for the prevention of thrombus formation in the extracorporeal circulation during haemodialysis.
Active ingredient Pharmaceutical form Package Therapeutic target
  • Enoxaparin
  • Solution for Injection
  • 20mg/0,2ml
  • 40mg/0,4ml
  • 60mg/0,6ml
  • 80mg/0,8ml
  • 100mg/1ml
  • Antithrombotic

Other products in "International"